Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy

Epilepsia

Volumn 49, Issue 1, 2008, Pages 108-116

  Conway, Miriam ^a   Cubbidge, Robert P ^b   Hosking, Sarah L ^a  

^a CITY UNIVERSITY   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

Epilepsy; Maximum daily dose; Quantitative; Vigabatrin; Visual field loss

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID; VIGABATRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; EPILEPSY; FEMALE; HUMAN; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; TREATMENT DURATION; VISUAL FIELD; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MIDDLE AGED; PERIMETRY; REGRESSION ANALYSIS; SCOTOMA; SEVERITY OF ILLNESS INDEX; VIGABATRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 37549068143     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.01249.x     Document Type: Article

References (37)

1. Arndt CF, Salle M, Derambure PH, Deefort-Dhellemmes S, Hache JC 2002) The effect on vision of associated treatment in patients taking vigabatrin: carbamazepine versus valporate. Epilepsia 43 : 812 817.
2. Bruni J, Guberman A, Vachon L, Desforges C 2000) Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. Seizure 9 : 224 232.
3. Chadwick D. (1999) Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 354 : 13 19.
4. Cubbidge RP. (2005) In Doshi S, Harvey W (Eds) Visual Fields, Elsevier Butterworth Heinemann Ltd. London, U.K.
5. Curcio CA, Sloan KR, Kalina RE, Hendrickson AE 1990) Human photoreceptor topography. J Comp Neurol 292 : 497 523.
6. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon A 1999) Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 106 : 1792 1798.
7. Electronic Medicines Compendium 2006). http://emc.medicines.org.uk/.
8. Frisén L, Malmgren K 2003) Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 81 : 466 473.
9. Frisén L. (2004) Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship. Acta Ophthalmol Scand 82 : 54 58.
10. Gerasimov MR, Schiffer WK, Brodie JD, Lennon IC, Taylor SJC, Dewey SL 2000) [gamma]-Aminobutyric acid mimetic drugs differentially inhibit the dopaminergic response to cocaine. Eur J Pharmacol 395 : 129 135.
11. Guberman A, Bruni J 2000) Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. Seizure 9 : 112 118.
12. Guerrini R. (2006) Epilepsy in children. Lancet 367 : 499 524.
13. Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TTJM, Van Veelen CWM 2000) Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 41 : 581 587.
14. Hardus P, Verduin WM, Engelsman M, Edelbroek PM, Segers JP, Berendschot TTJM, Stilma JS 2001) Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia 42 : 262 267.
15. Hosking SL, Roff Hilton EJ, Embleton SJ, Gupta AK 2003) Epilepsy patients treated with vigabatrin exhibit reduced ocular blood flow. Br J Ophthalmol 87 : 96 100.
16. Hudson C, Wild JM, O'Neill EC 1994) Fatigue effects during a single session of automated static threshold perimetry. Invest Ophthalmol Vis Sci 35 : 268 80.
17. Jonas JB, Schneider U, Naumann GO 1992) Count and density of human retinal photoreceptors. Graefes Arch Clin Exp Ophthalmol 230 : 505 510.
18. Kalviainen R, Nousiainen I, Mantyarvi M, Nikoskelainen E, Partanen J, Partanen K, Riekkinen P 1999) Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 53 : 922 926.
19. Kinirons P, Cavalleri GL, O'Rourke D, Doherty CP, Reid I, Logan P, Liggan B, Delanty N 2006) Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia 47 : 311 317.
20. Lawden MC, Eke T, Degg C, Harding GFA, Wild JM 1999) Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67 : 716 722.
21. Lynn JR 1969) Examination of the visual field in glaucoma. Invest Ophthalmol Vis Sci 8 : 76 84.
22. Malmgrem K, Ben-Menachem E, Frisén L 2001) Vigabatrin visual toxicity; evoloution and dose dependence. Epilepsia 42 : 609 615.
23. Manucheri K, Goodman S, Siviter L, Nightingale S 2000) A controlled study of vigabatrin and visual field abnormalities. Br J Ophthalmol 84 : 499 505.
24. Newman WD, Tocher K, Acheson JF 2002) Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 16 : 567 571.
25. Nicolson A, Leach JP, Chadwick DW, Smith DF 2002) The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry 73 : 327 329.
26. Nousiainen I, Mantyjarvi M, Kalviainen R 2001) No reversion in vigabatrin-associated visual field defects. Neurology 57 : 1916 1917.
27. Ravindran J, Blumbergs P, Crompton J, Pietris G, Waddy H 2001) Visual field loss associated with vigabatrin: pathological correlations. J Neurol Neurosurg Psychiatry 132 : 809.
28. Roff Hilton EJ, Cubbidge RP, Betts T, Comaish IF, Hosking SL 2002) Epilepsy patients treated with vigabatrin exhibit central visual function deficits. Epilepsia 43 : 1351 1359.
29. Russell-Eggitt IM, Mackey DA, Taylor DSI, Timms C, Walker JW 2000) Vigabatrin associated visual field defects in children. Eye 14 : 334 339.
30. Sanabria O, Feuer WJ, Anderson DR 1991) Pseudo-loss of fixation in automated perimetry. Ophthalmology 98 : 76 78.
31. Schiffer WK, Gerasimov MR, Bermel RA, Brodie JD, Dewey SL 2000) Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: a pet/microdialysis study. Life Sciences 66 : L169 L173.
32. Schiffer WK, Marsteller D, Dewey SL 2003) Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine. Psychopharmacologia 168 : 339 343.
33. Toggweiler S, Wieser HG 2001) Concentric visual field restriction under vigabatrin therapy: extent depends on the duration of drug intake. Seizure 10 : 420 423.
34. Trope GE, Britton R 1987) A comparison of Goldmann and Humphrey automated perimetry in patients with glaucoma. Br J Ophthalmol 71 : 489 493.
35. Versino M, Veggiotti P 1999) Reversibility of vigabatrin-induced visual-field defect. Lancet 354 : 486.
36. Wild JM, Martinez C, Reinshagenn G, Harding GFA 1999) Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40 : 1784 1794.
37. Wood JM, Wild JM, Hussey MK, Crews SJ 1987) Serial examination of the normal visual field using Octopus automated projectionperimetry: evidence for a learning effect. Acta Ophthalmol (Copenh) 65 : 326 33.